Trastuzumab, a recombinant humanized monoclonal antibody directed against the human HER2 receptor tyrosine kinase, mediates tumor-killing partially by inducing antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2 overexpressing tumor cells. Here, ERBB2 is linked to neoplasm.